Drug interaction potential of resveratrol

Drug Metabolism Reviews

Volumn 44, Issue 3, 2012, Pages 253-265

  Detampel, Pascal ^a   Beck, Mareike ^b   Krähenbühl, Stephan ^c   Huwyler, Jörg ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

cytochrome P450; drug metabolism; drug drug interactions; Resveratrol

Indexed keywords

AMIODARONE; ATORVASTATIN; CYCLOSPORIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; FELODIPINE; MEVINOLIN; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; RESVERATROL; SIMVASTATIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; VERAPAMIL;

AREA UNDER THE CURVE; DIET SUPPLEMENTATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; WINE;

ANIMALS; ANTICARCINOGENIC AGENTS; CARDIOTONIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; ENZYME INHIBITORS; FOOD-DRUG INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; STILBENES; VASODILATOR AGENTS; WINE;

EID: 84863786273     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2012.700715     Document Type: Review

References (84)

1. Almeida, L., Vaz-da-Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., et al. (2009). Pharmacokinetic and safety profile of transresveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53(Suppl 1):S7-S15.
2. Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., et al. (2002). Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387-398. (Pubitemid 34786278)
3. Bailey, D. G., Malcolm, J., Arnold, O., Spence, J. D. (1998). Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110. (Pubitemid 28342779)
4. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342. (Pubitemid 44764104)
5. Bebia, Z., Buch, S. C., Wilson, J. W., Frye, R. F., Romkes, M., Cecchetti, A., et al. (2004). Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 76:618-627. (Pubitemid 39601551)
6. Blanchard, N., Richert, L., Coassolo, P., Lavé, T. (2004). Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50, and inhibitor concentration. Curr Drug Metab 5:147-156. (Pubitemid 38515244)
7. Bogaards, J. J., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J., et al. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey, and man. Xenobiotica 30:1131-1152. (Pubitemid 32368013)
8. Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., et al. (2007). Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252. (Pubitemid 46984966)
9. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., et al. (2010). Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003-9011.
10. Calabrese, E. J., Mattson, M. P., Calabrese, V. (2010). Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol 29:980-1015.
11. Canistro, D., Bonamassa, B., Pozzetti, L., Sapone, A., Abdel-Rahman, S. Z., Biagi, G. L., et al. (2009). Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. Food Chem Toxicol 47:454-461.
12. Casper, R. F., Quesne, M., Rogers, I. M., Shirota, T., Jolivet, A., Milgrom, E., et al. (1999). Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56:784-790. (Pubitemid 29491181)
13. Chan, W. K., Delucchi, A. B. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67:3103-3112.
14. Chan, W. K., Nguyen, L. T., Miller, V. P., Harris, R. Z. (1998). Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 62:PL135-PL142. (Pubitemid 28077897)
15. Chang, T. K., Chen, J., Lee, W. B. (2001). Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299:874-882. (Pubitemid 33104954)
16. Chang, T. K., Yeung, R. K. (2001). Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol 79:220-226. (Pubitemid 32289660)
17. Choi, J.-S., Choi, B.-C., Kang, K. W. (2009). Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie 64:49-52.
18. Chow, H.-H. S., Garland, L. L., Hsu, C.-H., Vining, D. R., Chew, W. M., Miller, J. A., et al. (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168-1175.
19. Chun, Y. J., Kim, M. Y., Guengerich, F. P. (1999). Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262:20-24. (Pubitemid 29412616)
20. Ciolino, H. P., Yeh, G. C. (1999). Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56:760-767. (Pubitemid 29491178)
21. Crowell, J. A., Korytko, P. J., Morrissey, R. L., Booth, T. D., Levine, B. S. (2004a). Resveratrol-associated renal toxicity. Toxicol Sci 82:614-619. (Pubitemid 39600090)
22. Crowell, J. A., Levine, B. S., McCormick, D. L. (2004b). Resveratrol: drug development for cancer prevention (abstract no. 356) In: Abstracts of the 10th International Congress of Toxicology, July 11-15, 2004, Tampere, Finland. Toxicol Appl Pharmacol 197:218.
23. Delcò, F., Tchambaz, L., Schlienger, R., Drewe, J., Krähenbühl, S. (2005). Dose adjustment in patients with liver disease. Drug Saf 28:529-545.
24. Edwards, J. A., Beck, M., Riegger, C., Bausch, J. (2011). Safety of resveratrol with examples for high purity, trans-resveratrol, resVida® . Ann N Y Acad Sci 1215:131-137.
25. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., Baillie, T. A. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16. (Pubitemid 38134055)
26. Galetin, A., Gertz, M., Houston, J. B. (2010). Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 25:28-47.
27. Gill, M. T., Bajaj, R., Chang, C. J., Nichols, D. E., McLaughlin, J. L. (1987). 3,3′,5′-Tri-O-methylpiceatannol and 4,3′,5′-tri- Omethylpiceatannol: improvements over piceatannol in bioactivity. J Nat Prod 50:36-40.
28. Goldberg, D. M., Yan, J., Soleas, G. J. (2003). Absorption of three winerelated polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79-87. (Pubitemid 36126394)
29. Goosen, T. C., Cillié, D., Bailey, D. G., Yu, C., He, K., Hollenberg, P. F., et al. (2004). Bergamottin contribution to the grapefruit juicefelodipine interaction and disposition in humans. Clin Pharmacol Ther 76:607-617. (Pubitemid 39601550)
30. Gu, J., Wang, C., Fan, H., Ding, H., Xie, X., Xu, Y., et al. (2006). Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J Cardiovasc Pharmacol 47:711-721. (Pubitemid 44309666)
31. Gusman, J., Malonne, H., Atassi, G. (2001). A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22:1111-1117. (Pubitemid 32737324)
32. He, K., Iyer, K. R., Hayes, R. N., Sinz, M. W., Woolf, T. F., Hollenberg, P. F. (1998). Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252-259. (Pubitemid 28194348)
33. Hebbar, V., Shen, G., Hu, R., Kim, B.-R., Chen, C., Korytko, P. J., et al. (2005). Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299-2314. (Pubitemid 40313418)
34. Hong, S.-P., Choi, D.-H., Choi, J.-S. (2008). Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Cardiovasc Ther 26:269-275.
35. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., et al. (2011). Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4:1419-1425.
36. Ingelman-Sundberg, M. (2004). Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Arch Pharmacol 369:89-104.
37. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220. (Pubitemid 127696281)
38. Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., et al. (2010). Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a doubleblind, placebo-controlled, crossover investigation. Am J Clin Nutr 91:1590-1597.
39. Kondratyuk, T. P., Park, E.-J., Marler, L. E., Ahn, S., Yuan, Y., Choi, Y., et al. (2011). Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol Nutr Food Res 55:1249-1265.
40. Kopp, P. (1998). Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox"? Eur J Endocrinol 138:619-620.
41. Kupferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J., Krähenbühl, S. (1995). Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20-28.
42. Lilja, J. J., Kivistö, K. T., Backman, J. T., Lamberg, T. S., Neuvonen, P. J. (1998). Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64:655-660. (Pubitemid 29011385)
43. Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., Ducharme, M. P. (2002). Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302:369-373. (Pubitemid 34680460)
44. Martignoni, M., Groothuis, G. M., de Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYPmediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894. (Pubitemid 44911538)
45. McLaughlin, L. A., Dickmann, L. J., Wolf, C. R., Henderson, C. J. (2008). Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos 36:1322-1331. (Pubitemid 351929317)
46. Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671.
47. Mikstacka, R., Gnojkowski, J., Baer-Dubowska, W. (2002). Effect of natural phenols on the catalytic activity of cytochrome P450 2E1. Acta Biochim Pol 49:917-925. (Pubitemid 135702943)
48. Mugford, C. A., Kedderis, G. L. (1998). Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30:441-498. (Pubitemid 28384436)
49. Nebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., Dalton, T. P. (2000). Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 59:65-85.
50. Nunes, T., Almeida, L., Rocha, J.-F., Falcão, A., Fernandes-Lopes, C., Loureiro, A. I., et al. (2009). Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 49:1477-1482.
51. Offman, E. M., Freeman, D. J., Dresser, G. K., Munoz, C., Bend, J. R., Bailey, D. G. (2001). Red wine-cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 70:17-23. (Pubitemid 32678798)
52. Ozdemir, M., Aktan, Y., Boydag, B. S., Cingi, M. I., Musmul, A. (1998). Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 23:55-59. (Pubitemid 28230326)
53. Patel, K. R., Scott, E., Brown, V. A., Gescher, A. J., Steward, W. P., Brown, K. (2011). Clinical trials of resveratrol. Ann N Y Acad Sci 1215:161-169.
54. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L., Price, N. L., Labinskyy, N., et al. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8:157-168.
55. Piver, B., Berthou, F., Dreano, Y., Lucas, D. (2001). Inhibition of CYP3A, CYP1A, and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 125:83-91. (Pubitemid 33043758)
56. Piver, B., Berthou, F., Dreano, Y., Lucas, D. (2003). Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 73:1199-1213. (Pubitemid 36733564)
57. Piver B, Fer M, Vitrac X, Merillon J-M, Dreano Y, Berthou F, Lucas D. (2004). Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol 68:773-782. (Pubitemid 38953459)
58. Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., et al. (2002). The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86:774-778. (Pubitemid 34250822)
59. Raucy, J. L. (2003). Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31:533-539.
60. Regev-Shoshani, G., Shoseyov, O., Kerem, Z. (2004). Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem Biophys Res Commun 323:668-673. (Pubitemid 39221147)
61. Revel, A., Raanani, H., Younglai, E., Xu, J., Rogers, I., Han, R., et al. (2003). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a] pyrene. J Appl Toxicol 23:255-261.
62. Sale, S., Verschoyle, R. D., Boocock, D., Jones, D. J. L., Wilsher, N., Ruparelia, K. C., et al. (2004). Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer 90:736-744. (Pubitemid 38297218)
63. Sandhu, M. S., Dunger, D. B., Giovannucci, E. L. (2002). Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972-980. (Pubitemid 34814726)
64. Sergent, T., Dupont, I., Van der Heiden, E., Scippo, M.-L., Pussemier, L., Larondelle, Y., et al. (2009). CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells. Toxicol Lett 191:216-222.
65. Sirtris, GlaxoSmithKline. (2011). A clinical study to assess the safety and activity of SRT501 alone or in combination with bortezomib in patients with multiple myeloma. In: ClinicalTrials.gov [Online]. Bethesda (MD): National Library of Medicine (US). Available at: http://clinicaltrials.gov/show/ NCT00920556 NLM Identifier: NCT00920556. Accessed on December 2, 2011.
66. Smoliga, J. M., Baur, J. A., Hausenblas, H. A. (2011). Resveratrol and health - a comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129-1141.
67. Snyder, S. A., Gollner, A., Chiriac, M. I. (2011). Regioselective reactions for programmable resveratrol oligomer synthesis. Nature 474:461-466.
68. Soleas, G. J., Yan, J., Goldberg, D. M. (2001). Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl 757:161-172. (Pubitemid 32424469)
69. Stervbo, U., Vang, O., Bonnesen, C. (2007). A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem 101:449-457. (Pubitemid 44333178)
70. Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., et al. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14:612-622.
71. Todesco, L., Bodmer, M., Vonwil, K., Häussinger, D., Krähenbühl, S. (2009). Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. Chem Biol Interact 180:472-477.
72. Trusov, N. V., Guseva, G. V., Aksenov, I. V., Avren'eva, L. I., Kravchenko, L. V., Tutelyan, V. A. (2010). Effects of combined treatment with resveratrol and indole-3-carbinol. Bull Exp Biol Med 149:213-218.
73. Tsunoda, S. M., Harris, R. Z., Christians U., Velez, R. L., Freeman, R. B., Benet, L. Z., et al. (2001). Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 70:462-467. (Pubitemid 33135326)
74. U.S. FDA (2005). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. [Online]. Silver Spring, Maryland, USA: FDA. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ ucm078932.pdf. Accessed on 06 December 2011.
75. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., et al. (2011). What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 6:e19881.
76. Weinshilboum, R. (2003). Inheritance and drug response. N Engl J Med 348:529-537.
77. Williams, L. D., Burdock, G. A., Edwards, J. A., Beck, M., Bausch, J. (2009). Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 47:2170-2182.
78. Wong, R. H. X., Howe, P. R. C., Buckley, J. D., Coates, A. M., Kunz, I., Berry, N. M. (2011). Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 21:851-856.
79. Yang, C. S., Pan, E. (2012). The effects of green tea polyphenols on drug metabolism. Expert Opin Drug Metab Toxicology 8:677-689.
80. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., van Breemen, R. B. (2003). Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 17:307-313. (Pubitemid 36193670)
81. Yu, W., Fu, Y.-C., Wang, W. (2011). Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113:752-759.
82. Zhang, L., Zhang, Y. D., Strong, J. M., Reynolds, K. S., Huang, S.- M. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.
83. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304. (Pubitemid 40477790)
84. Zhou, S.-F., Liu, J.-P., Chowbay, B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295.